The study will evaluate the safety of and immune response to AG-707 in up to 84 patients with herpes simplex virus type 2 (HSV-2), an infection affecting one in five Americans over the age of 12.
AG-707 (recombinant heat shock protein 70 polyvalent peptide complex) is a heat shock protein-based vaccine that is designed to activate the immune system to target HSV-2 infection in a broad population of patients.
“AG-707 is designed to stimulate a potent T-cell response against the virus to control and reduce the severity of infection,” said Dr Garo Armen, chairman and CEO of Antigenics. “With this application of heat shock protein technology, our hope is to be able to provide an effective new treatment option for millions of people suffering from genital herpes.”